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Background: Matrix Metalloproteinases (MMPs) are directly responsible for pathogenesis of
periodontal diseases and their activity is regulated by Tissue Inhibitor of Metalloprotei-
nases (TIMPs). This study was aimed to evaluate changes in gingival crevicular ﬂuid (GCF)
levels of MMP-1 and TIMP-1 in periodontal health and disease.
Materials and method: Clinical parameters were recorded and GCF samples were collected
from 30 subjects with chronic generalised periodontitis and 20 periodontally healthy
subjects. Subjects with periodontitis underwent scaling and root planing (SRP). GCF
samples were collected and clinical parameters were recorded again after 1 month of
SRP. GCF levels of MMP-1 and TIMP-1 were detected by ELISA.
Results: GCF levels of MMP-1 were signiﬁcantly increased in subjects with periodontitis at
baseline (P0) as compared to periodontally healthy subjects (C). GCF levels of MMP-1
reduced signiﬁcantly in subjects with periodontitis after treatment (P1) as compared to P0.
GCF levels of TIMP-1 were signiﬁcantly reduced in P0 as compared to C. GCF levels of TIMP-
1 increased signiﬁcantly in P1 as compared to P0.
Conclusion: Substantial elevation in GCF levels of MMP-1 and reduction in TIMP-1 were
found in periodontitis as compared to healthy subjects. GCF levels of MMP-1 and TIMP-1
improved signiﬁcantly after treatment.
& 2014 Published by Elsevier B.V.Introduction
Periodontitis is a multifactorial infectious disease charac-
terised by destruction of the bone and connective tissue
caused primarily by speciﬁc periodontopathic bacteria and
modiﬁed by interaction with host and environmental factorra Park, Near Rani Tower,
. P. Popat).[1]. The initial host response comprises an innate recognition
of microbial components – lipopolysaccharides (LPS) complex
by host cells and the subsequent production of inﬂammatory
mediators, such as; eicosanoids, reactive oxygen species,
Matrix Metalloproteinases (MMPs), chemokines and cytokines
which are directly responsible for periodontal destruction [2].Kalawad Road, Rajkot 360005, Gujarat, India. Tel.: þ91 9824232272.
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teases that are released from different cell types including
macrophages, leucocytes, ﬁbroblasts and other resident cells
[3]. They are believed to participate in embryonic development,
arthritis, angiogenesis, morphogenesis, reproduction, tissue
resorption, tissue remodelling and tumour growth, invasion
and its metastasis through breakdown of extracellular matrix
(ECM) [4]. MMP-1, prototype interstitial collagenase is the ﬁrst
vertebrate collagenase [5]. It is distributed widely in tissues and
expressed by ﬁbroblasts, keratinocytes, endothelial cells, osteo-
blasts, chondrocytes, and monocytes/macrophages [6,7].
Activity of various MMPs is regulated at multiple levels
(transcriptional, post-transcriptional, and post-translational)
and also by endogenous inducible inhibitors, the Tissue
Inhibitors of Metalloproteinases (TIMPs) [3]. TIMPs, family of
proteins, appear to regulate matrix degradation both by
proteinase inhibition and by blockage of autocatalytic MMP
activation [8]. Among all the TIMPs, TIMP-1 inhibit collage-
nase more effectively. TIMP-1 is a 30-kDa glycoprotein that is
synthesised and secreted by most connective tissue cells as
well as by macrophages; it can be identiﬁed in most body
ﬂuids [9].
Previously, increased expression of MMP-1 mRNA was
found in inﬂamed gingival tissue of subjects with chronic
periodontitis as compared to healthy controls in various
studies [7,10–13]. But, very few studies available demonstrat-
ing changes in gingival crevicular ﬂuid (GCF) levels of MMP-1
and TIMP-1 in periodontal health and in periodontal disease.
Also, only few reports available showing association between
clinical parameters and GCF levels of MMP-1 and TIMP-1.
Therefore, the present study was aimed to evaluate changes
in gingival crevicular ﬂuid (GCF) levels of MMP-1 and TIMP-1
in periodontal health and disease before and after period-
ontal treatment. Furthermore, we also correlated biochemical
parameters with clinical parameters.Materials and method
Study population
30 subjects with chronic generalised periodontitis (13 male
and 17 female, mean age 37 yr) and 20 periodontally healthy
subjects (10 male and 10 female, mean age 34 yr) were
enrolled in this study from Department of Periodontology,
during August 2012 to November 2012. All selected subjects
were in good general health. Selected subjects had age range
of 21–55 yr.
The periodontal status of all included subjects were
assessed according to the classiﬁcation of periodontal disease
by the American Academy of Periodontology [14]. Diagnosis of
subjects with chronic generalised periodontitis was based on
clinical and radiographic ﬁndings. Subjects with probing depth
(PD) Z4 mm and clinical attachment loss (CAL) Z2 mm in at
least 30% of sites and radiographic evidence of bone loss were
selected. While subjects who had clinically healthy gingiva, no
clinical attachment loss (CAL) and probing depth (PD) o3 mm
were categorised as periodontally healthy subjects.
The following exclusion criteria were used; (1) presence of
o20 permanent teeth, (2) individual with history of systemicconditions such as heart disease, diabetes, Tuberculosis, etc., (3)
postmenopausal women and smokers, (4) any medication use
that could affect the manifestations of periodontal disease,
such as chronic antibiotic use, phenytoin, cyclosporine,
anti-inﬂammatory drugs, or calcium channel blockers, (5)
individual with periodontal abscess, necrotising ulcerative dis-
eases, aggressive periodontitis, (6) those who have received any
type of periodontal treatment in past 6 months or subjects on
periodontal maintenance therapy.
Clinical examination
All selected subjects were fully informed about purpose of the
study and consent was obtained. Clinical evaluation was
based on the following indices: gingival index (GI) [15], plaque
index (PI) [16], probing depths (PD) and Clinical attachment
loss (CAL). Clinical parameters for each subject were recorded
by a single examiner with full mouth clinical examination,
excluding third molars. All clinical parameters were recorded
on 4 sites per tooth (mesiobuccal, buccal, distobuccal, palatal)
using calibrated UNC-15 Probe. Probing depth and CAL were
measured with a calibrated UNC-15 Probe, using free gingival
margin and cement-enamel junction as reference point.
Collection and storage of gingival crevicular ﬂuid sample
Subjects were made to sit comfortably in an upright position
on the dental chair with proper illumination. The most
severely affected upper anterior sextant (maxillary incisors
and the canine teeth) was chosen for the study due to good
accessibility in that area. The test site was air dried, isolated
with cotton rolls and supragingival plaque was removed
without touching the marginal gingiva. Colour coded 1–5 μl
calibrated volumetric microcapillary pipettes were used for
collecting GCF samples. Samples were collected by placing
the tip of the pipette in to gingival crevice. The test sites
which did not express any volume of GCF and micropipette
contaminated with blood and saliva were excluded from the
study. Samples were immediately transferred to plastic vials
and stored at 70 1C till the time of the assay.
Periodontal treatment
After clinical examination and GCF collection, subject with
periodontitis underwent periodontal treatment at the same
appointment. Periodontal treatment included oral hygiene
instructions as well as scaling and root planning (SRP).
Scaling and root planing were performed using extremely
sharp sickles, Gracey curettes and ultrasonic instruments.
After 1 month of SRP, clinical parameters were recorded and
GCF samples were collected from same site of each subject
with periodontitis. During whole study period of a month
each subject with periodontitis were recalled at intervals of 1
week and plaque control measures were performed.
Enzyme Linked Immunoabsorbent Assay (ELISA)
GCF levels of MMP-1 and TIMP-1 were analysed using ELISA,
performed by using a commercial ELISA kit (RayBiosHuman
MMP-1 ELISA Kit and RayBiosHuman TIMP-1 ELISA Kit)
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were expelled from micropipettes with jet of air using blower
provided with pipette and by further washing with ﬁxed
amount of diluent. The samples were diluted with the diluent
provided with ELISA kit in the ratio of 1:40 for MMP-1 and 1:100
for TIMP-1. All assay procedures were carried out according to
the manufacturer's instructions. After preparation, samples
and standards were incubated 2.5 h at room temperature in
precoated wells. Then the solution was discarded and each
well was washed 4 times. 100 μl prepared biotin antibody was
added and incubated 1 h at room temperature. Followed by
washing, 100 μl prepared HRP Streptavidin solution was added
and incubated 45min at room temperature. After washing,
100 μl tetramethylbenzedine one-step substrate reagent was
added and incubated 30min at room temperature and then
the reaction was stopped by adding 50 μl Stop Solution to each
well. Optical densities of standards and samples were obtained
by reading immediately at 450 nmwavelength. Standard curve
was plotted with standard concentration on the x-axis and
absorbance on the y-axis to determine levels of MMP-1 and
TIMP-1.Statistical analysis
Data analysis was performed using the statistical package
SPSS 19 software. The clinical and biochemical parameters of
subjects with chronic periodontitis before periodontal treat-
ment (P0) and after periodontal treatment (P1) were analysed
using Wilcoxon signed-rank test. Mann–Whitney U test was
used to determine signiﬁcant difference among healthy con-
trols (C) and subjects with periodontitis before treatment (P0)
and among healthy controls (C) and subjects with period-
ontitis after treatment (P1). Correlation (r) between clinical
and biochemical parameters among subjects with period-
ontitis were analysed with Pearson's correlation test. The P
value o0.05 was considered as statistically signiﬁcant.Fig. 1 – Comparison of GCF levels of MMP-1 among subjects
with chronic periodontitis at baseline (P0), at the 1 month
after treatment (P1) and healthy controls (C).Results
Biochemical parameters
GCF levels of MMP-1 were signiﬁcantly higher among P0
(20.36723.55 ng/ml) as compared to C (7.29711.83) (P valueTable 1 – Comparison GCF levels of MMP-1, TIMP-1, MMP-1/TIM
before treatment (P0), after treatment (P1) and healthy control
Periodontitis
baseline (P0)
Periodontitis 1 mo
treatment (P1)
MMP-1 (ng/ml) 20.36723.55 9.26715.9
TIMP-1 (ng/ml) 113.657137.11 280.397162.15
MMP-1/TIMP-1 0.8871.47 0.1370.46
Gingival Index (GI) 1.9470.08 0.9570.24
Plaque Index (PI) 2.1270.2 1.0570.23
Probing Depth (PD) 4.2470.54 3.6670.47
Clinical Attachment
Loss (CAL)
2.0370.69 1.6670.710.026). GCF levels of MMP-1 were signiﬁcantly reduced in P1
(9.26715.9 ng/ml) as compared to P0 (P value 0.004). There
was no signiﬁcant difference found in GCF levels of MMP-1
among C and P1 (P value 0.63) (Table 1, Fig. 1).
GCF levels of TIMP-1 were signiﬁcantly lower among P0
(113.657137.11 ng/ml) as compared to C (351.46799.5 ng/ml)
(Po0.001). GCF levels of TIMP-1 were signiﬁcantly raised in P1
(280.397162.15) as compared to P0 (Po0.001). There was no
signiﬁcant difference found in GCF levels of TIMP-1 among C
and P1 (P value 0.087) (Table 1, Fig. 2).
The ratio of MMP-1 to TIMP-1 in GCF was signiﬁcantly
higher in P0 (0.8871.47) than C (0.0870.26) (P value 0.021), but
it reduced signiﬁcantly in P1 (0.1370.46) as compared to P0 (P
value 0.002) and there was no signiﬁcant difference found in
ratio of MMP-1 to TIMP-1 among P1 and C (P value 0.671)
(Table 1, Fig. 3).Clinical parameters
Gingival Index (GI) scores (Mean7SD) were signiﬁcantly higher
among P0 (1.9470.08) as compared to C (0.6570.27) (Po0.001).
GI scores were signiﬁcantly reduced in P1 (0.9570.24) as
compared to P0 (Po0.001). Statistically signiﬁcant difference
was found between P1 and C (Po0.001) (Table 1).P-1 and clinical parameters in subjects with periodontitis
(C). (Mean7Standard Deviation).
nth after Control (C) P value
P0–P1 P0–C P1–C
7.29711.83 0.004 0.026 0.63
351.46799.5 o0.001 o0.001 0.087
0.0870.26 0.002 0.021 0.671
0.6570.27 o0.001 o0.001 o0.001
0.6970.3 o0.001 o0.001 o0.001
1.5270.35 o0.001 o0.001 o0.001
0 o0.001 o0.001 o0.001
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among P0 (2.1270.2) as compared to C (0.6970.3) (Po0.001). PI
scores were signiﬁcantly reduced in P1 (1.0570.23) as compared
to P0 (Po0.001). Statistically signiﬁcant difference was found
between P1 and C (Po0.001) (Table 1).
Probing Depth (PD) scores (Mean7SD) were signiﬁcantly
higher among P0 (4.2470.54) as compared to C (1.5270.35)
(Po0.001). PD scores were signiﬁcantly reduced in P1 (3.667
0.47) as compared to P0 (Po0.001). Statistically signiﬁcant
difference was found between P1 and C (Po0.001) (Table 1).Fig. 3 – Comparison of ratio of GCF levels of MMP-1/TIMP-1
among subjects with chronic periodontitis at baseline (P0), at
the 1 month after treatment (P1) and healthy controls (C).
Table 2 – Correlation among GCF levels of MMP-1, TIMP-1 and
MMP-1 TIMP-1 G
MMP-1
Correlation r 1 0.22
Signiﬁcance P 0.088
TIMP-1
Correlation r 0.22 1 
Signiﬁcance P 0.088 o
Fig. 2 – Comparison of GCF levels of TIMP-1 among subjects
with chronic periodontitis at baseline (P0), at the 1 month
after treatment (P1) and healthy controls (C).Clinical Attachment Loss (CAL) scores (Mean7SD) were
signiﬁcantly higher among P0 (2.0370.69) as compared to C
(070) (Po0.001). CAL scores were signiﬁcantly reduced in P1
(1.6670.71) as compared to P0 (Po0.001). Statistically signiﬁ-
cant difference was found between P1 and C (Po0.001)
(Table 1).
Correlation among clinical and biochemical parameters
Statistically signiﬁcant negative correlation was found
between GCF levels of MMP-1 and TIMP-1 (r 0.22, P 0.088).
GCF levels of MMP-1 had shown signiﬁcant positive correla-
tion with GI (r 0.28, P 0.028) and PI (r 0.28, P 0.031). GCF levels
of TIMP-1 had shown signiﬁcantly negative correlation with
GI (r 0.62, Po0.001), PI (r 0.65, Po0.001), PD (r 0.47,
Po0.001) and CAL (r 0.36, P 0.005) (Table 2).Discussion
Periodontitis is an inﬂammatory disease of supporting struc-
tures of teeth resulting in destruction of alveolar bone and
connective tissue. Possible mechanism for the degradation of
collagen ﬁbres and extracellular matrix in periodontitis is
independent and/or cooperative action of both human and
bacterial proteinases [17,18]. Periodontal destruction is most
likely caused by host cell derived MMPs [19]. It has been
suggested that MMP-1 may play an important role in the
initiation of collagen degradation in periodontal disease [7].
Previously, increased expression of MMP-1 mRNA was found
in inﬂamed gingival tissue of subjects with chronic period-
ontitis as compared to healthy controls in various studies
[7,10–13]. Tissue inhibitors of metalloproteinases bind to
Matrix Metalloproteinases and irreversibly inhibit their
enzyme activity. Altered TIMP expression is also known to
occur in many disease processes and affects the processing of
extracellular matrix [20]. Moreover, it was speculated that
TIMP-1 appears to be more effectively inhibit MMP-1 [9].
Hence, we investigated changes in GCF levels of MMP-1 and
TIMP-1 in subjects with periodontal health and disease.
Wide varieties of immunological method are used to
detect GCF levels of MMPs and TIMPs. In comparison to other
assay systems, ELISA tests have several advantages including
improved sensitivity (at least compared to zymography), ease
of use, moderately rapid throughput, the ability to quantify
enzyme levels and the ﬂexibility to test for multiple MMPs
in single samples. Moreover, ELISAs may be more adap-
table to use in ofﬁce settings because of their simpler and
more robust instrumentation [21]. Therefore ELISA has beenclinical parameters.
I PI PD CAL
0.28 0.28 0.1 0.08
0.028 0.031 0.427 0.534
0.62 0.65 0.47 0.36
0.001 o0.001 o0.001 0.005
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gingival crevicular ﬂuid in present study.
In this study, we found that GCF levels of MMP-1 were
signiﬁcantly elevated in subjects with periodontitis before
treatment (P0) as compared to healthy subjects (C), which is
in agreement with previous studies [22,23]. It is in contrast
with Birdt et al. [24], stated that there was no signiﬁcant
difference in GCF levels of MMP-1 in diseased and healthy
sites. This variation in ﬁnding can be due to difference in
sample size as well as other difference in methodology of
both studies. We also found that GCF levels of MMP-1 were
signiﬁcantly reduced in subjects with chronic periodontitis 1
month after scaling and root planning (P1) as compared to P0
and remained close to GCF levels MMP-1 of healthy subjects
(C). These ﬁndings are in accordance with Tuter et al. [23].
In present study, we found that GCF levels of TIMP-1 were
signiﬁcantly reduced in P0 as compared to C which is in
accordance with previous ﬁndings by Bildt et al. [24]. GCF
levels of TIMP-1 were increased signiﬁcantly in P1 as com-
pared to P0. These ﬁndings are in accordance with Pozo et al.
[25] and Tuter et al. [26]. Furthermore, our ﬁndings are
consistent with Haerian et al. [27] who reported that the
GCF levels of TIMP increases at follow up examination at 6
weeks hygiene phase therapy.
In present study, we found the ratio of MMP-1/TIMP-1
signiﬁcantly higher in subjects with periodontitis before
treatment and it decreased signiﬁcantly after treatment.
Thus, it can be suggested that balance in GCF levels of
MMP-1 and TIMP-1 also play signiﬁcant role in maintaining
healthy periodontal condition.
We also found that all the clinical parameters improved
signiﬁcantly in periodontitis after SRP. Considerable evidences
support role of SRP as an essential and effective therapy for
reductions in inﬂammation and progression of periodontal
diseases. This reduction in inﬂammation inhibits up-regulated
MMPs expression in periodontitis, resulting in decreased
MMP-1 after SRP [28,29]. Several possible explanations for the
increased TIMP-1 levels after periodontal therapy: (1) a reduc-
tion in MMP-1, which would bind to free TIMP; however, the
regulation of TIMP-1 may not solely be dependent on the
MMP-1 [9], (2) the decreased levels of TIMP-1 in periodontally
diseased subjects may be due to the selective degradation of
TIMP-1 by neutrophil elastase or the inactivation of TIMP-1 by
neutrophils themselves following oxidant release [30,31], (3)
the increased levels of its TIMP-1 may reﬂect its involvement
in the healing process, (4) unidentiﬁed mechanisms for clear-
ance of MMP-TIMP-1 complexes [27].
On comparison of biochemical and clinical parameters in
present study showed signiﬁcantly negative correlation
among GCF levels of MMP-1 and TIMP-1 which is accordance
with Tuter et al. [23]. We also found signiﬁcantly negative
correlation of GCF levels of TIMP-1 with all the clinical
parameters (GI, PI, PD, CAL) which are in accordance with;
Pozo et al. [25], found negative correlation among GCF levels
of TIMP-1 and probing depth and CAL and Tuter et al. [26],
found negative correlation between GCF levels of TIMP-1 and
gingival index, plaque index and probing depth.
While, signiﬁcantly positive correlation of GCF levels of
MMP-1 was found with GI and PI, which is in contrast with
Tuter et al. [26] who did not ﬁnd any signiﬁcant correlation.Furthermore, Villela et al. [32] reported a positive but rather
weak correlation between PD and GI and collagenase activity
while Gangbar et al. [33] failed to ﬁnd any correlations between
collagenase activity and clinical parameters. Different methods
of GCF sampling and laboratory techniques as well as variations
in reporting the results may inﬂuence the variation found in
correlation between clinical and biochemical parameters in
various studies.
In present study, we used ELISA to determine GCF levels of
MMP-1 and TIMP-1, which measure total enzyme level (both
active and latent) in GCF rather than active enzyme level. It
can be possible that proportional amount of active enzyme
would be low after treatment. Thus, it is advisable in future to
perform study that can discriminate between active and
latent (inactive) form of enzymes. In the present study we
evaluated GCF levels of MMP-1 and TIMP-1 in periodontitis
before and after SRP but, longitudinal studies which deter-
mine prognostic values of GCF levels of MMP-1 and TIMP-1
will be required to carry out in future to further clarify the
role of MMP-1 and TIMP-1 in periodontal destruction. Under-
standing of expression patterns and levels of MMPs in
periodontal tissues and various oral ﬂuids help for the future
development of functional and/or immunological MMP diag-
nostic tools to monitor the course of periodontitis as well as
the effects of various treatment modalities of periodontitis.Conclusion
Within the limits of present study we concluded that a
substantial elevation in GCF levels of MMP-1 and reduction
in GCF levels of TIMP-1 were found in subjects with period-
ontitis as compared with healthy controls. GCF levels of
MMP-1 decreased and TIMP-1 increased after scaling and root
planing as compared with their level before treatment. This
indicate important role of MMP-1 and TIMP-1 in periodontal
destruction.
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